GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Alkermes, Inc. (ALKS) [hlAlert]

Rating:
Buy ALKS
up 390.14 %

Alkermes, Inc. (ALKS) rated Buy by Merriman Curhan Ford

Posted on: Thursday,  Jun 5, 2008  8:25 AM ET by Merriman Curhan Ford

Merriman Curhan Ford rated Buy Alkermes, Inc. (NASDAQ: ALKS) on 06/05/2008, when the stock price was $12.48. Since
then, Alkermes, Inc. has gained 390.14% as of 01/21/2016's recent price of $61.17.
If you would have followed this Merriman Curhan Ford's recommendation on ALKS, you would have gained 390.14% of your investment in 2786 days.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.

We occupy a unique niche among our investment banking peers: we offer our clients both traditional sell-side equity research and primary market research, and we focus on high-potential sectors such as CleanTech, Consumer/Internet/Media, Health Care and Tech/Telecom. Our institutional and corporate clients get the best of both worlds: expertise from our analysts and access to experts through our Panel Intelligence platform.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/5/2008 8:25 AM Buy
None
12.48
as of 12/24/2008
1 Week down  -4.56 %
1 Month down  -32.60 %
3 Months down  -27.82 %
1 YTD down  -27.41 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy